Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth ​up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are ‌traditio...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。